Rankings
▼
Calendar
VCYT (Veracyte, Inc.) Stock Financials & Earnings | Market Cap Arena
VCYT
Veracyte, Inc.
Mkt Cap
$3B
Healthcare
·
Biotechnology
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$517M
Net Income (TTM)
$66M
EPS (TTM)
$0.82
Free Cash Flow (TTM)
$126M
Gross Margin
70.6%
Op. Margin
9.0%
Net Margin
12.8%
FCF Margin
24.4%
P/S Ratio (TTM)
5.2x
P/E Ratio (TTM)
40.2x
YoY Rev Growth
+16.0%
Employees
—
Earnings Reports
▶
Q4 2025
NEW
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$82M
$56M
-$10M
Q2 23
$90M
$56M
-$8M
Q3 23
$90M
$62M
-$32M
Q4 23
$98M
$69M
-$36M
Q1 24
$97M
$62M
-$5M
Q2 24
$114M
$78M
$5M
Q3 24
$116M
$79M
$12M
Q4 24
$119M
$79M
$4M
Q1 25
$114M
$80M
$3M
Q2 25
$130M
$90M
-$5M
Q3 25
$132M
$91M
$23M
Q4 25
$141M
$105M
$26M
marketcaparena.com
Revenue Breakdown
VCYT
Veracyte, Inc.
Revenue Breakdown
Q4 2025
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
8.6x
—
Q2 23
8.1x
—
Q3 23
7.8x
—
Q4 23
7.4x
—
Q1 24
7.1x
—
Q2 24
6.7x
—
Q3 24
6.3x
—
Q4 24
6.0x
110.6x
Q1 25
5.8x
80.8x
Q2 25
5.6x
101.4x
Q3 25
5.4x
88.1x
Q4 25
5.2x
40.2x
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
-$2M
-$3M
Q2 23
$17M
$13M
Q3 23
$14M
$11M
Q4 23
$16M
$13M
Q1 24
-$9M
-$11M
Q2 24
$30M
$27M
Q3 24
$30M
$28M
Q4 24
$25M
$20M
Q1 25
$5M
$4M
Q2 25
$34M
$32M
Q3 25
$45M
$42M
Q4 25
$53M
$48M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$993K
Q2 23
$4M
Q3 23
$3M
Q4 23
$2M
Q1 24
$2M
Q2 24
$3M
Q3 24
$2M
Q4 24
$4M
Q1 25
$2M
Q2 25
$1M
Q3 25
$3M
Q4 25
$4M
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
+21.6%
+11.9%
Q2 23
+24.0%
+17.7%
Q3 23
+19.2%
+42.9%
Q4 23
+22.3%
+56.0%
Q1 24
+17.5%
+9.2%
Q2 24
+26.7%
+11.6%
Q3 24
+28.6%
-14.8%
Q4 24
+20.8%
-14.4%
Q1 25
+18.2%
+9.9%
Q2 25
+13.8%
+23.3%
Q3 25
+13.8%
+4.9%
Q4 25
+18.5%
+0.2%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$8M
9.7%
Q2 23
$10M
11.5%
Q3 23
$7M
8.1%
Q4 23
$8M
7.6%
Q1 24
$8M
8.3%
Q2 24
$10M
8.6%
Q3 24
$9M
7.5%
Q4 24
$10M
8.1%
Q1 25
$11M
9.6%
Q2 25
$11M
8.4%
Q3 25
$11M
8.2%
Q4 25
$11M
7.8%
marketcaparena.com
OpEx Breakdown
R&D
G&A
S&M
Quarter
R&D
G&A
S&M
Q1 23
$13M
$40M
$6M
Q2 23
$13M
$43M
$7M
Q3 23
$13M
$16M
$24M
Q4 23
$19M
$41M
$7M
Q1 24
$16M
$43M
$6M
Q2 24
$16M
$47M
$7M
Q3 24
$18M
$40M
$7M
Q4 24
$19M
$47M
$8M
Q1 25
$18M
$52M
$7M
Q2 25
$16M
$14M
$43M
Q3 25
$16M
$43M
$7M
Q4 25
$21M
$1M
$43M
marketcaparena.com
Revenue Segments
Biopharmaceutical And Other
Product
Testing
Quarter
Biopharmaceutical And Other
Product
Testing
Q1 23
$6M
$4M
$72M
Q2 23
$5M
$4M
$82M
Q3 23
$4M
$4M
$82M
Q4 23
$4M
$4M
$90M
Q1 24
$3M
$4M
$90M
Q2 24
$4M
$4M
$107M
Q3 24
$3M
$3M
$110M
Q1 25
$4M
$4M
$107M
Q2 25
$4M
$4M
$122M
Q3 25
$1M
$3M
$128M
Q4 25
$686K
$4M
$136M
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$178M
$0
$178M
Q2 23
$191M
$0
$191M
Q3 23
$202M
$0
$202M
Q4 23
$216M
$0
$216M
Q1 24
$209M
$0
$209M
Q2 24
$236M
$0
$236M
Q3 24
$274M
$0
$274M
Q4 24
$239M
$50M
$289M
Q1 25
$186M
$101M
$287M
Q2 25
$219M
$101M
$321M
Q3 25
$316M
$51M
$366M
Q4 25
$363M
$50M
$413M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
72M
+0.5%
Q2 23
72M
+0.4%
Q3 23
73M
+0.4%
Q4 23
73M
+0.4%
Q1 24
75M
+2.3%
Q2 24
77M
+3.2%
Q3 24
78M
+1.7%
Q4 24
80M
+1.8%
Q1 25
80M
+0.2%
Q2 25
80M
-0.2%
Q3 25
80M
-0.3%
Q4 25
81M
+2.1%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 14
$229K
167
FY 15
$258K
192
FY 16
$301K
216
FY 17
$292K
246
FY 18
$341K
270
FY 19
$340K
354
FY 20
$367K
320
FY 21
$288K
761
FY 22
$377K
787
FY 23
$443K
815
FY 24
$541K
824
FY 25
$796
650K
marketcaparena.com